Abstract:Diagnosing patients suffering from psychotic disorders is far from being achieved with molecular support, despite all the efforts to study these disorders from different perspectives. Characterizing the proteome of easily obtainable blood specimens, such as the peripheral blood mononuclear cells (PBMCs), has particular interest in biomarker discovery and generating pathophysiological knowledge. This approach has been explored in psychiatry, and while generating valuable information, it has not translated into meaningful biomarker discovery. In this project, we report the proof-of-concept of a methodology that aims to explore further information obtained with classical proteomics approaches that is easily overlooked. PBMC samples from first-episode psychosis and control subjects were subjected to a SWATH-MS approach, and the classical protein relative quantification was performed, where 389 proteins were found to be important to distinguish the two groups. Individual analysis of the quantified peptides was also performed, highlighting peptides of unchanged proteins that were significantly altered. With the combination of protein- and peptide-centered proteomics approaches, it is possible to highlight that information about proteoforms, namely regulation at the peptide level possibly due to post-translational modifications, is routinely overlooked and that its diagnostic potential should be further explored. Significance Our exploratory findings highlight the potential of MS-based proteomics strategies, combining protein- and peptide-centered approaches, to aid clinical decision-making in first-episode psychosis, helping to establish early biomarkers for schizophrenia and other psychotic disorders. Particularly, the less popular peptide-centered approach allows the identification/measurement of overlooked modulated peptides that may have potential biomarker characteristics. The application in parallel of protein- and peptide-centered strategies is transversal to research of other diseases, potentially allowing a more comprehensive characterization of the metabolic/pathophysiological alterations related to a specific disease.

Psychiatric research: psychoproteomics, degradomics and systems biology

Bioinformatics in Psychiatric Genetics

Neuroproteomics and its applications in research on nicotine and other drugs of abuse.

Advances in Proteomics Allow Insights Into Neuronal Proteomes

Advances in Proteomic and Metabolomic Profiling of Neurodegenerative Diseases

Radiomics; A Potential Next “Omics” in Psychiatric Disorders; An Introduction

Maximizing Analytical Performance in Biomolecular Discovery with LC-MS: Focus on Psychiatric Disorders

Epigenetic Research in Neuropsychiatric Disorders: the "Tissue Issue"

PROTEOMIC STUDY OF DRUG ADDICTION

Background data for the identification of protein biomarkers in CSF by proteomic approaches

Multimodal Neuroimaging of the Effect of Serotonergic Psychedelics on the Brain

Mass Spectrometry Strategies for Clinical Metabolomics and Lipidomics in Psychiatry, Neurology, and Neuro-Oncology

The Underlying Neurobiological Mechanisms of Psychosis: Focus on Neurotransmission Dysregulation, Neuroinflammation, Oxidative Stress, and Mitochondrial Dysfunction

Biological Mechanism-based Neurology and Psychiatry: A BACE1/2 and Downstream Pathway Model

Transcriptomics and magnetic resonance imaging in major psychiatric disorders

Precision Medicine in Depression: The Role of Proteomics and Metabolomics in Personalized Treatment Approaches

Computational Psychopharmacology: a Translational and Pragmatic Approach

Unraveling Psychiatric Disorders through Neural Single-Cell Transcriptomics Approaches

Biosensors for psychiatric biomarkers in mental health monitoring

Focus on fatty acids in the neurometabolic pathophysiology of psychiatric disorders

Proteomic analysis of peripheral blood mononuclear cells in first episode psychosis – Protein and peptide-centered approaches to elucidate potential diagnostic biomarkers